Dephosphorylated cofilin expression is associated with poor prognosis in cases of human breast cancer: a tissue microarray analysis

Figures & data

Figure 1 Tissue microarray and immunohistochemistry staining of P-cofilin in invasive ductal breast cancer tumors.

Notes: (A) Tissue microarray 1 (150 cases), 1× magnification; (B) tissue microarray 2 (150 cases), 1× magnification; (C) negative expression of P-cofilin, 200× magnification; and (D) positive expression of P-cofilin, 200× magnification.
Abbreviation: P-cofilin, phosphorylated cofilin.

Figure 2 Association of P-cofilin with overall survival among patients with invasive ductal breast cancer.

Abbreviation: P-cofilin, phosphorylated cofilin.

Figure 3 Association of cofilin with overall survival among P-cofilin-negative patients with invasive ductal breast cancer.

Abbreviation: P-cofilin, phosphorylated cofilin.

Figure 4 Association of cofilin with overall survival among P-cofilin-positive patients with invasive ductal breast cancer.

Abbreviation: P-cofilin, phosphorylated cofilin.

Table 1 Cofilin with or without phosphorylation for predicting overall survival in invasive ductal breast cancer

P-cofilin	Cofilin	Death (n)	Survival (n)	P-value
Negative	Negative	54	154	0.002
	Positive	15	17
Positive	Negative	11	22	0.355
	Positive	7	10

Abbreviation: P-cofilin, phosphorylated cofilin.

Table 2 Clinicopathological characteristics of breast cancer with different cofilin expression

Pathological category	Cases, n (%)	Negative cofilin	Positive cofilin	P-value
Age (years)				0.155
<50	87 (36.6%)	79	8
≥50	153 (63.8%)	129	24
T category				0.136
T1	67 (27.9%)	62	5
T2	146 (60.8%)	125	21
T3/T4	27 (11.3%)	21	6
N category				0.510
N0	106 (44.2%)	93	13
N1	67 (27.9%)	55	12
N2	47 (19.6%)	43	4
N3	20 (8.3%)	17	3
TNM stage				0.688
0/I	33 (13.8%)	30	3
II	129 (53.8%)	110	19
III	78 (32.5%)	68	10
ER status				0.177
Negative	94 (39.2%)	78	16
Positive	146 (60.8%)	130	16
PR status				0.075
Negative	130 (54.2%)	108	22
Positive	110 (45.8%)	100	10
HER-2 status				0.380
Negative	180 (75.0%)	158	22
Positive	60 (25.0%)	50	10
Ki-67 status				0.002
Negative	168 (70.0%)	153	15
Positive	72 (30.0%)	55	17
Molecular subtypes				0.100
Luminal A	101 (42.1%)	94	7
Luminal B	52 (21.7%)	43	9
HER-2	31 (12.9%)	25	6
TNBC	56 (23.3%)	46	10

Abbreviations: ER, estrogen receptor; HER-2, human epidermal growth factor receptor 2; PR, progesterone receptor; TNBC, triple-negative breast cancer.

Table 3 Univariate and multivariate analysis of factors that predict overall survival in invasive ductal breast cancer

Pathological category	Univariate analysis			Multivariate analysis
	P-value	HR	95% CI	P-value	HR	95% CI
Cofilin status	0.002	1.349	1.112–1.637	0.007	1.321	1.079–1.617
Age (years)
<50 vs ≥50	0.404	0.815	0.503–1.318
T category
T1 vs T2 vs T3/T4	0.055	1.476	0.991–2.199
N category
N0 vs N1 vs N2 vs N3	0.001	1.956	1.324–2.890	0.686	0.923	0.627–1.359
TNM stage
0/I vs II vs III	0.001	1.917	1.347–2.729	0.012	2.279	1.199–4.333
ER status
Negative vs positive	0.030	0.591	0.368–0.950	0.452	1.481	0.532–4.124
PR status
Negative vs positive	0.012	0.529	0.322–0.869	0.538	0.807	0.408–1.597
HER-2 status
Negative vs positive	0.444	1.234	0.720–2.116
Ki-67 status
Negative vs positive	0.341	1.130	0.879–1.452
Molecular subtypes
Luminal A vs Luminal B vs	0.004	1.319	1.094–1.592	0.124	1.390	0.914–2.114
HER-2 vs TNBC

Abbreviations: ER, estrogen receptor; HER-2, human epidermal growth factor receptor 2; HR, hazard ratio; PR, progesterone receptor; TNBC, triple-negative breast cancer.